On February 18, 2026 Iaso Therapeutics, Inc., a biotechnology company redefining infectious disease prevention with its novel synthetic vaccine platform, reported that it will present at the 2026 World Vaccine Congress in Washington, D.C., on Tuesday, March 31. President and CEO Robert Forgey, MS, MBA, will provide an overview of Iaso’s technology and commercial strategy during his live presentation at the Innovator Showcase.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
2026 World Vaccine Congress
Date: Tuesday, March 31
Time: 1:30 p.m. ET
Session: Innovator Showcase
Location: Walter E. Washington Convention Center, Washington, D.C.
The presentation will showcase how Iaso’s synthetic vaccine platform delivers the broad protection and scalable production needed to combat infectious diseases, including the escalating threat of antimicrobial resistance, to transform global health.
In addition to the presentation, Iaso will host meetings with industry stakeholders, including investors and strategic partners, at Booth 589 in the Emerging Business Zone.
(Press release, Iaso Therapeutics, FEB 18, 2026, View Source [SID1234662750])